![Timothy A. Wurst](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Timothy A. Wurst
Directeur Technique/Scientifique/R&D chez
TVAX Biomedical I LLC
Profil
Mr. Timothy A. Wurst is Vice President-Clinical & Regulatory Affairs at TVAX Biomedical, Inc. and Vice President-Clinical Development at TVAX Biomedical I LLC.
He received his undergraduate degree from The University of Colorado and an MBA from San Diego State University.
Postes actifs de Timothy A. Wurst
| Sociétés | Poste | Début |
|---|---|---|
TVAX Biomedical I LLC
 TVAX Biomedical I LLC Part of TVAX Biomedical, Inc., TVAX Biomedical I LLC is a clinical stage development company based in Lenexa, KS. TVAX Biomedical I LLC specializes in the development of a novel targeted cell-based immunotherapy for the treatment of cancer. The company's immunotherapeutic cancer treatment platform is based on over 50 years of scientific and medical research into the interactions between cancer and the immune system. TVAX Immunotherapy employs the natural ability of T cells to kill cancer cells and has demonstrated the ability to effectively treat numerous cancers without many of the undesirable side effects associated with radiation and chemotherapy. The key difference between TVAX Biomedical I LLC and other cancer immunotherapy companies is that it uses both cancer vaccine pretreatment to generate cancer-specific T cells and activated "killer" T cell treatment, which has demonstrated significant efficacy. The proprietary treatment has received orphan product designation from the FDA for the prevention and treatment of any primary central nervous system malignancy, providing the company with seven years of marketing exclusivity following FDA marketing approval. The company was founded by Catherine E. Lucasey, Frank P. Holladay, Gray W. Wood. Gray W. Wood has been the CEO of the company since 2004. | Directeur Technique/Scientifique/R&D | 01/01/2010 |
Anciens postes connus de Timothy A. Wurst
| Sociétés | Poste | Fin |
|---|---|---|
| TVAX BIOM | Directeur Technique/Scientifique/R&D | - |
Formation de Timothy A. Wurst
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
5
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
TVAX Biomedical, Inc.
 TVAX Biomedical, Inc. BiotechnologyHealth Technology Manufactures and sells healthcare products | Health Technology |
San Diego State University
 San Diego State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Colorado
 The University of Colorado Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TVAX Biomedical I LLC
TVAX Biomedical I LLC Part of TVAX Biomedical, Inc., TVAX Biomedical I LLC is a clinical stage development company based in Lenexa, KS. TVAX Biomedical I LLC specializes in the development of a novel targeted cell-based immunotherapy for the treatment of cancer. The company's immunotherapeutic cancer treatment platform is based on over 50 years of scientific and medical research into the interactions between cancer and the immune system. TVAX Immunotherapy employs the natural ability of T cells to kill cancer cells and has demonstrated the ability to effectively treat numerous cancers without many of the undesirable side effects associated with radiation and chemotherapy. The key difference between TVAX Biomedical I LLC and other cancer immunotherapy companies is that it uses both cancer vaccine pretreatment to generate cancer-specific T cells and activated "killer" T cell treatment, which has demonstrated significant efficacy. The proprietary treatment has received orphan product designation from the FDA for the prevention and treatment of any primary central nervous system malignancy, providing the company with seven years of marketing exclusivity following FDA marketing approval. The company was founded by Catherine E. Lucasey, Frank P. Holladay, Gray W. Wood. Gray W. Wood has been the CEO of the company since 2004. |
